A new class of drugs targeting the genetic material of skin cancer has been successfully tested in humans for the first time. This opens the way to new treatments for a range of conditions from skin cancers to eye diseases.
A new retrospective study suggests that anti-HER2 treatments have anti-cancer effects in a small subset of patients with advanced non-small cell lung cancer who harbor specific mutations in the HER2 protein.
Does consumption of regular orange juice cause drug interactions, or should all citrus fruits be avoided?
A new class of tumor-fighting drugs that use RNA interference were studied for their safety and preliminary efficacy.
Which medicines can be split or crushed for administration?
A new gentler chemotherapy drug has been designed to be less toxic to a young woman's fertility. This is the first cancer drug tested while in development for its effect on fertility using a novel in vitro test.
Cancer drug shortages led to treatment delays and changes, research complications, more medication errors and adverse outcomes, and higher costs.
New research indicates that leukemic cells can be eradicated by removing a carbohydrate modification that is displayed on the cell's surface. This discovery is an important advance against leukemia.
New evidence suggests that an otherwise promising class of drugs may actually increase the risk of tumors spreading to bone. The drugs block survival signals that many cancer cells rely on to stay alive; however, targeting the same protein that makes tumors vulnerable to death also overactivates osteoclasts.
Persons with non-small cell lung cancer who received definitive radiotherapy survived longer when beta-blockers were added to the mix.
A national drug shortage has been linked to a higher rate of relapse among children, teenagers, and young adults with Hodgkin lymphoma enrolled in a national clinical trial.
Older patients may not respond as well as younger persons to conventional therapies for chronic lymphocytic leukemia, a new study indicates.
A new immunomodulatory drug under FDA review significantly increased survival in persons with multiple myeloma, including older patients.
The FDA has expanded the indication for abiraterone acetate (Zytiga tablets) to combat metastatic castration-resistant prostate cancer.
The final data from a phase II study confirmed the high degree of activity of quizartinib in persons with acute myeloid leukemia.
Ibrutinib, which targets the Bruton's tyrosine kinase to combat chronic lymphocytic leukemia, showed promising results in two phase II studies.
A drug used for metastatic breast cancer after several previous treatments may improve survival when administered earlier in the disease course.
Persons with inflammatory breast cancer who were using statins at time of diagnosis had better progression-free survival than did nonusers.
Leukemia stem cells that overcome drug therapy can be thwarted when deprived of RAD52, a protein key to DNA repair of these cancer cells.
Vorinostat, already used in lymphoma, reduces the risk of graft-versus-host disease after allogeneic hematopoietic stem-cell transplantation.
Newly approved for prostate cancer, enzalutamide may be useful as a therapeutic agent in breast cancer that evades other treatments.
The 32-mg, single IV dose of the anti-nausea drug Zofran (ondansetron) will no longer be sold due to the potential for serious cardiac risks.
Ten years of adjuvant treatment with tamoxifen provided women with ER-positive breast cancer greater protection against late recurrence and death from breast cancer compared with the current standard of 5 years of tamoxifen.
The American Society of Clinical Oncology has released a nearly 100-page report detailing the year's most significant developments in cancer.
Use of the oral antidiabetes drug metformin improved survival in women with ovarian cancer, according to the findings of a retrospective case-control study.
Persons with metastatic colorectal cancer or gastrointestinal stromal tumors may garner some survival benefit from regorafenib after standard treatments have failed.
Heart failure is relatively common in older women undergoing breast cancer treatment, but trastuzumab therapy appears to raise the risk even more.
Denosumab improved overall survival in persons with lung cancer and bone metastases more effectively than did zoledronic acid.
Early end-of-life talks are associated with less aggressive care and greater use of hospice services when patients do reach their final days.
After adjustment for confounding variables, metformin use independently predicts survival.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|